Sparrow COVID-19 Outpatient Treatment

Outpatient Treatment Overview

Sparrow provides COVID-19 outpatient treatments for eligible patients that include Evusheld, Molnupiravir and Paxlovid oral medication, and Monoclonal Antibody IV infusion. Talk to your primary care physician about these treatment options as they must be ordered by your physician.

Order Forms for Physicians
Resources and Fact Sheets

Evusheld Treatment

Treatment to protect eligible high-risk individuals from COVID-19 before they are exposed

Sparrow Hospital’s outpatient infusion clinic located on the 2^nd floor of the Herbert-Herman Cancer Center is now accepting orders from qualified healthcare providers for Evusheld treatments to protect eligible high-risk individuals from COVID-19.

Evusheld is not a replacement for COVID-19 vaccines. Everyone eligible to receive one of the safe and effective COVID-19 vaccines should do so.

What is Evusheld?

The U.S. Food and Drug Administration issued an Emergency Use Authorization for AstraZeneca’s Evusheld, a prevention medication for certain high-risk individuals that can help protect them from COVID-19 before they are exposed to the virus. Evusheld is the first pre-exposure prophylaxis product for COVID-19 apart from vaccines.

Evusheld is a combination of two medications given together: tixagevimab and cilgavimab. Both are monoclonal antibodies, which are lab-made proteins that act like antibodies made by your immune system to fight an infection. Evusheld is administered by two injections immediately given one after another.

Who is eligible to receive Evusheld treatment?

It’s authorized for people ages 12 and older who weigh at least 88 pounds. You also can’t be currently infected with COVID-19 or have a known recent exposure to the virus; that is, be in your isolation or quarantine periods. Your doctor will need to determine if you meet the current criteria.

How to be referred for an Evusheld injection

Check with your doctor to see if you are eligible. A doctor must submit an order for a patient to receive the Evushield injections. Physicians can download and fax the order form to Sparrow’s Outpatient Infusion Center as noted on the form.

Where can I learn more about Evusheld treatment?

Oral Antiviral Medication

Oral medications for high-risk patients diagnosed with COVID-19

COVID-19 Oral Medications Available at Sparrow Pharmacy Plus Locations

Sparrow Pharmacy Plus has the COVID-19 oral medications Paxlovid and Molnupiravir. They can be ordered at all Pharmacy Plus locations. Patients can take advantage of Sparrow's local pharmacy delivery as well as drive-thru services at Grand Ledge and the Sparrow Health Center Lansing locations. Get the complete list of pharmacy locations, hours, and more.

Paxlovid and Molnupiravir

Paxlovid and Molnupiravir are oral antiviral medications used to treat mild-to-moderate COVID-19 in patients 12 years of age and older who are at high risk for progression to severe COVID-19, including hospitalization or death, and who meet the current Priority Eligibility Criteria.

How do I know if I am a candidate for oral antiviral medications?

Your healthcare provider will determine if you are a candidate for Paxlovid or Molnupiravir. At a minimum you must have mild-to-moderate COVID-19, be over 12 years of age and weigh at least 40 kg (88 lbs) and be at high risk for severe COVID-19, including hospitalization or death, meeting certain high-risk eligibility criteria established by MDHHS. Current eligibility information for the public is available at this website: Michigan.gov COVID-19 Therapeutics information page.

Monoclonal Antibody IV Infusion

Treatment for high-risk patients diagnosed with COVID-19

Sparrow has established several COVID-19 Monoclonal Antibody IV Infusion Clinics to safely treat qualifying high-risk COVID-19 positive patients in an outpatient setting.

Treatment limited to highest risk patients

Two of the three monoclonal antibody treatments that we have depended on to keep COVID-19 patients from becoming seriously ill do not appear to work against Omicron. The national supply of the one treatment that appears to be effective in treating Omicron is very limited.

To ensure that patients at the highest risk receive treatment, Sparrow will follow the State of Michigan’s updated eligibility prioritization criteria to limit treatment to the highest risk patients.

You're eligible to be treated with monoclonal antibodies at Sparrow if you have mild to moderate symptoms of COVID-19 for 7 days or less, you’ve tested positive for COVID-19 based on a test ordered by a medical provider, and you meet the State of Michigan eligibility prioritization criteria.

How to be referred to the clinic

Patients must check with their doctor to see if they are eligible. A doctor must submit an order for a patient to receive the IV treatment. Orders can be found in Epic, or physicians can download and fax a completed order form to the desired clinic location as noted on the form.

Where can I learn more about the monoclonal antibody IV treatment?